Vertex Pharmaceuticals Inc. diskutieren
Vertex Pharmaceuticals Inc.
WKN: 882807 / Symbol: VRTX / Name: Vertex / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
427,80 €
0,73 %
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "outperform" rating reaffirmed by analysts at Evercore ISI. They now have a $530.00 price target on the stock, up previously from $475.00.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "outperform" rating reaffirmed by analysts at Scotiabank.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $541.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $580.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Oppenheimer Holdings, Inc. from $540.00 to $600.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by HC Wainwright from $591.00 to $641.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Citigroup Inc. from $575.00 to $585.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Bank of America Corporation from $571.00 to $598.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals (VRTX) had its price target raised by Morgan Stanley from $570.00 to $596.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Discuss Choice Hotels Internatl.